{"@context":{"@vocab":"https://cir.nii.ac.jp/schema/1.0/","rdfs":"http://www.w3.org/2000/01/rdf-schema#","dc":"http://purl.org/dc/elements/1.1/","dcterms":"http://purl.org/dc/terms/","foaf":"http://xmlns.com/foaf/0.1/","prism":"http://prismstandard.org/namespaces/basic/2.0/","cinii":"http://ci.nii.ac.jp/ns/1.0/","datacite":"https://schema.datacite.org/meta/kernel-4/","ndl":"http://ndl.go.jp/dcndl/terms/","jpcoar":"https://github.com/JPCOAR/schema/blob/master/2.0/"},"@id":"https://cir.nii.ac.jp/crid/1360848656190200320.json","@type":"Article","productIdentifier":[{"identifier":{"@type":"DOI","@value":"10.1007/s00535-012-0645-5"}},{"identifier":{"@type":"URI","@value":"http://link.springer.com/content/pdf/10.1007/s00535-012-0645-5.pdf"}},{"identifier":{"@type":"URI","@value":"http://link.springer.com/article/10.1007/s00535-012-0645-5/fulltext.html"}},{"identifier":{"@type":"URI","@value":"http://link.springer.com/content/pdf/10.1007/s00535-012-0645-5"}},{"identifier":{"@type":"PMID","@value":"22850869"}}],"resourceType":"学術雑誌論文(journal article)","dc:title":[{"@value":"Entecavir and interferon-α sequential therapy in Japanese patients with hepatitis B e antigen-positive chronic hepatitis B"}],"description":[{"notation":[{"@value":"The outcomes of sequential therapy with lamivudine followed by interferon have been unsatisfactory in Japanese patients with hepatitis B envelope antigen (HBeAg)-positive chronic hepatitis B. However, the efficacy of sequential therapy with entecavir and interferon remains unclear.Twenty-four HBeAg-positive patients (23 men and 1 woman; mean age 39 ± 7 years) received entecavir 0.5 mg alone for 36-52 weeks, followed by entecavir plus interferon-α for 4 weeks, and lastly by interferon-α alone for 20 weeks. Twenty-three patients had genotype C infection, and one had genotype A infection.No entecavir-resistant mutant variants emerged in any patient. Hepatitis flare occurred in three patients during interferon-α treatment after the withdrawal of entecavir, but none had hepatic decompensation. Serum hepatitis B surface antigen levels did not change during or after therapy. Serum hepatitis B core-related antigen levels were significantly decreased at the start (P0.0001) and at the end of interferon-α treatment (P0.0001), but returned to baseline levels after treatment. Twenty-four weeks after the completion of the sequential therapy, a sustained biochemical, virological, and serological response was achieved in 5 (21 %) patients. The proportion of patients in whom HBeAg was lost during entecavir treatment was significantly higher among those with a sustained response than among those with no response (P = 0.015).The rate of response to sequential therapy with entecavir and interferon-α in Japanese patients with HBeAg-positive chronic hepatitis B was not higher than the rate in previous studies of lamivudine followed by interferon."}]}],"creator":[{"@id":"https://cir.nii.ac.jp/crid/1420845751148484864","@type":"Researcher","personIdentifier":[{"@type":"KAKEN_RESEARCHERS","@value":"20423874"},{"@type":"NRID","@value":"1000020423874"},{"@type":"ORCID","@value":"0000-0002-4028-4381"},{"@type":"NRID","@value":"9000271848605"},{"@type":"NRID","@value":"9000367025627"},{"@type":"NRID","@value":"9000365534072"},{"@type":"NRID","@value":"9000314382611"},{"@type":"NRID","@value":"9000404845621"},{"@type":"NRID","@value":"9000002333884"},{"@type":"NRID","@value":"9000021472715"},{"@type":"NRID","@value":"9000409619120"},{"@type":"NRID","@value":"9000021554128"},{"@type":"NRID","@value":"9000065451240"},{"@type":"NRID","@value":"9000019974484"},{"@type":"NRID","@value":"9000019974501"},{"@type":"NRID","@value":"9000020158011"},{"@type":"NRID","@value":"9000240056659"},{"@type":"NRID","@value":"9000006764068"},{"@type":"NRID","@value":"9000403298971"},{"@type":"NRID","@value":"9000406020280"},{"@type":"NRID","@value":"9000399799546"},{"@type":"NRID","@value":"9000021518307"},{"@type":"NRID","@value":"9000406036283"},{"@type":"NRID","@value":"9000402898106"},{"@type":"NRID","@value":"9000021575850"},{"@type":"NRID","@value":"9000021758335"},{"@type":"RESEARCHMAP","@value":"https://researchmap.jp/read0210159"}],"foaf:name":[{"@value":"Masaru Enomoto"}]},{"@id":"https://cir.nii.ac.jp/crid/1380848656190200210","@type":"Researcher","foaf:name":[{"@value":"Shuhei Nishiguchi"}]},{"@id":"https://cir.nii.ac.jp/crid/1420001326208123264","@type":"Researcher","personIdentifier":[{"@type":"KAKEN_RESEARCHERS","@value":"30291595"},{"@type":"NRID","@value":"1000030291595"},{"@type":"ORCID","@value":"0000-0001-9119-4864"},{"@type":"NRID","@value":"9000000485055"},{"@type":"NRID","@value":"9000002333755"},{"@type":"NRID","@value":"9000329440332"},{"@type":"NRID","@value":"9000271848606"},{"@type":"NRID","@value":"9000248229503"},{"@type":"NRID","@value":"9000021576341"},{"@type":"NRID","@value":"9000367025620"},{"@type":"NRID","@value":"9000259328985"},{"@type":"NRID","@value":"9000018273325"},{"@type":"NRID","@value":"9000365534076"},{"@type":"NRID","@value":"9000314382609"},{"@type":"NRID","@value":"9000404845619"},{"@type":"NRID","@value":"9000258515866"},{"@type":"NRID","@value":"9000021472722"},{"@type":"NRID","@value":"9000409619118"},{"@type":"NRID","@value":"9000347123761"},{"@type":"NRID","@value":"9000258211767"},{"@type":"NRID","@value":"9000259329151"},{"@type":"NRID","@value":"9000021606038"},{"@type":"NRID","@value":"9000021554135"},{"@type":"NRID","@value":"9000021215904"},{"@type":"NRID","@value":"9000347123155"},{"@type":"NRID","@value":"9000021576755"},{"@type":"NRID","@value":"9000021577014"},{"@type":"NRID","@value":"9000021456601"},{"@type":"NRID","@value":"9000019974486"},{"@type":"NRID","@value":"9000019974503"},{"@type":"NRID","@value":"9000020157875"},{"@type":"NRID","@value":"9000021760438"},{"@type":"NRID","@value":"9000240056660"},{"@type":"NRID","@value":"9000377381644"},{"@type":"NRID","@value":"9000021535754"},{"@type":"NRID","@value":"9000415434184"},{"@type":"NRID","@value":"9000018797771"},{"@type":"NRID","@value":"9000021604729"},{"@type":"NRID","@value":"9000391408341"},{"@type":"NRID","@value":"9000265562545"},{"@type":"NRID","@value":"9000021639453"},{"@type":"NRID","@value":"9000020514349"},{"@type":"NRID","@value":"9000327452274"},{"@type":"NRID","@value":"9000248229372"},{"@type":"NRID","@value":"9000399799547"},{"@type":"NRID","@value":"9000021518311"},{"@type":"NRID","@value":"9000391588867"},{"@type":"NRID","@value":"9000414221323"},{"@type":"NRID","@value":"9000411514492"},{"@type":"NRID","@value":"9000406036280"},{"@type":"NRID","@value":"9000402898108"},{"@type":"NRID","@value":"9000021575856"},{"@type":"NRID","@value":"9000405866682"},{"@type":"NRID","@value":"9000243721067"},{"@type":"NRID","@value":"9000248229099"},{"@type":"NRID","@value":"9000021392897"},{"@type":"NRID","@value":"9000412650927"},{"@type":"NRID","@value":"9000248228515"},{"@type":"NRID","@value":"9000021639375"},{"@type":"NRID","@value":"9000021518128"},{"@type":"NRID","@value":"9000021758339"},{"@type":"NRID","@value":"9000020584054"},{"@type":"NRID","@value":"9000369739096"},{"@type":"NRID","@value":"9000410735294"},{"@type":"RESEARCHMAP","@value":"https://researchmap.jp/tamori-a"}],"foaf:name":[{"@value":"Akihiro Tamori"}]},{"@id":"https://cir.nii.ac.jp/crid/1380848656190200320","@type":"Researcher","foaf:name":[{"@value":"Sawako Kobayashi"}]},{"@id":"https://cir.nii.ac.jp/crid/1380848656190200337","@type":"Researcher","foaf:name":[{"@value":"Hiroki Sakaguchi"}]},{"@id":"https://cir.nii.ac.jp/crid/1380848656190200330","@type":"Researcher","foaf:name":[{"@value":"Susumu Shiomi"}]},{"@id":"https://cir.nii.ac.jp/crid/1380848656190200201","@type":"Researcher","foaf:name":[{"@value":"Soo Ryang Kim"}]},{"@id":"https://cir.nii.ac.jp/crid/1380848656190200329","@type":"Researcher","foaf:name":[{"@value":"Hirayuki Enomoto"}]},{"@id":"https://cir.nii.ac.jp/crid/1380848656190200064","@type":"Researcher","foaf:name":[{"@value":"Masaki Saito"}]},{"@id":"https://cir.nii.ac.jp/crid/1380848656190200197","@type":"Researcher","foaf:name":[{"@value":"Hiroyasu Imanishi"}]},{"@id":"https://cir.nii.ac.jp/crid/1420845751160426880","@type":"Researcher","personIdentifier":[{"@type":"KAKEN_RESEARCHERS","@value":"30271191"},{"@type":"NRID","@value":"1000030271191"},{"@type":"NRID","@value":"9000364914345"},{"@type":"NRID","@value":"9000021413377"},{"@type":"NRID","@value":"9000021395707"},{"@type":"NRID","@value":"9000317151109"},{"@type":"NRID","@value":"9000241184179"},{"@type":"NRID","@value":"9000364914309"},{"@type":"NRID","@value":"9000406035693"},{"@type":"NRID","@value":"9000018425179"},{"@type":"NRID","@value":"9000364914354"},{"@type":"NRID","@value":"9000003171579"},{"@type":"NRID","@value":"9000006119542"},{"@type":"NRID","@value":"9000020561954"},{"@type":"NRID","@value":"9000021373399"},{"@type":"NRID","@value":"9000367025629"},{"@type":"NRID","@value":"9000347123824"},{"@type":"NRID","@value":"9000021489016"},{"@type":"NRID","@value":"9000365534075"},{"@type":"NRID","@value":"9000254058702"},{"@type":"NRID","@value":"9000254061294"},{"@type":"NRID","@value":"9000404845620"},{"@type":"NRID","@value":"9000342800376"},{"@type":"NRID","@value":"9000021472741"},{"@type":"NRID","@value":"9000021435178"},{"@type":"NRID","@value":"9000409619122"},{"@type":"NRID","@value":"9000254061474"},{"@type":"NRID","@value":"9000258211771"},{"@type":"NRID","@value":"9000413555745"},{"@type":"NRID","@value":"9000307252848"},{"@type":"NRID","@value":"9000002242099"},{"@type":"NRID","@value":"9000389566783"},{"@type":"NRID","@value":"9000021554147"},{"@type":"NRID","@value":"9000021510380"},{"@type":"NRID","@value":"9000021432974"},{"@type":"NRID","@value":"9000021339261"},{"@type":"NRID","@value":"9000254448394"},{"@type":"NRID","@value":"9000363291091"},{"@type":"NRID","@value":"9000021346660"},{"@type":"NRID","@value":"9000019974488"},{"@type":"NRID","@value":"9000019974505"},{"@type":"NRID","@value":"9000021760445"},{"@type":"NRID","@value":"9000020598102"},{"@type":"NRID","@value":"9000391679707"},{"@type":"NRID","@value":"9000347123176"},{"@type":"NRID","@value":"9000356628786"},{"@type":"NRID","@value":"9000392873402"},{"@type":"NRID","@value":"9000021319337"},{"@type":"NRID","@value":"9000020547117"},{"@type":"NRID","@value":"9000258558999"},{"@type":"NRID","@value":"9000021394730"},{"@type":"NRID","@value":"9000021509846"},{"@type":"NRID","@value":"9000020552600"},{"@type":"NRID","@value":"9000347123025"},{"@type":"NRID","@value":"9000364914350"},{"@type":"NRID","@value":"9000364914460"},{"@type":"NRID","@value":"9000005808265"},{"@type":"NRID","@value":"9000364914308"},{"@type":"NRID","@value":"9000020545561"},{"@type":"NRID","@value":"9000378091828"},{"@type":"NRID","@value":"9000254061412"},{"@type":"NRID","@value":"9000018894143"},{"@type":"NRID","@value":"9000405692818"},{"@type":"NRID","@value":"9000020529995"},{"@type":"NRID","@value":"9000254061247"},{"@type":"NRID","@value":"9000399520334"},{"@type":"NRID","@value":"9000399799551"},{"@type":"NRID","@value":"9000364914362"},{"@type":"NRID","@value":"9000021518325"},{"@type":"NRID","@value":"9000020568556"},{"@type":"NRID","@value":"9000391588868"},{"@type":"NRID","@value":"9000402898109"},{"@type":"NRID","@value":"9000005807879"},{"@type":"NRID","@value":"9000004419166"},{"@type":"NRID","@value":"9000021575869"},{"@type":"NRID","@value":"9000405866684"},{"@type":"NRID","@value":"9000398380316"},{"@type":"NRID","@value":"9000242719424"},{"@type":"NRID","@value":"9000398289546"},{"@type":"NRID","@value":"9000020654068"},{"@type":"NRID","@value":"9000345215745"},{"@type":"NRID","@value":"9000347123911"},{"@type":"NRID","@value":"9000402460275"},{"@type":"NRID","@value":"9000345447340"},{"@type":"NRID","@value":"9000356683217"},{"@type":"NRID","@value":"9000364914365"},{"@type":"NRID","@value":"9000364914467"},{"@type":"NRID","@value":"9000021518133"},{"@type":"NRID","@value":"9000021458039"},{"@type":"NRID","@value":"9000021758345"},{"@type":"NRID","@value":"9000254451820"},{"@type":"NRID","@value":"9000413755611"},{"@type":"RESEARCHMAP","@value":"https://researchmap.jp/read0188645"}],"foaf:name":[{"@value":"Norifumi Kawada"}]}],"publication":{"publicationIdentifier":[{"@type":"PISSN","@value":"09441174"},{"@type":"EISSN","@value":"14355922"}],"prism:publicationName":[{"@value":"Journal of Gastroenterology"}],"dc:publisher":[{"@value":"Springer Science and Business Media LLC"}],"prism:publicationDate":"2012-08-02","prism:volume":"48","prism:number":"3","prism:startingPage":"397","prism:endingPage":"404"},"reviewed":"false","dc:rights":["http://www.springer.com/tdm"],"url":[{"@id":"http://link.springer.com/content/pdf/10.1007/s00535-012-0645-5.pdf"},{"@id":"http://link.springer.com/article/10.1007/s00535-012-0645-5/fulltext.html"},{"@id":"http://link.springer.com/content/pdf/10.1007/s00535-012-0645-5"}],"createdAt":"2012-08-01","modifiedAt":"2019-05-29","foaf:topic":[{"@id":"https://cir.nii.ac.jp/all?q=Adult","dc:title":"Adult"},{"@id":"https://cir.nii.ac.jp/all?q=Male","dc:title":"Male"},{"@id":"https://cir.nii.ac.jp/all?q=Guanine","dc:title":"Guanine"},{"@id":"https://cir.nii.ac.jp/all?q=Interferon-alpha","dc:title":"Interferon-alpha"},{"@id":"https://cir.nii.ac.jp/all?q=Middle%20Aged","dc:title":"Middle Aged"},{"@id":"https://cir.nii.ac.jp/all?q=Antiviral%20Agents","dc:title":"Antiviral Agents"},{"@id":"https://cir.nii.ac.jp/all?q=Drug%20Administration%20Schedule","dc:title":"Drug Administration Schedule"},{"@id":"https://cir.nii.ac.jp/all?q=Young%20Adult","dc:title":"Young Adult"},{"@id":"https://cir.nii.ac.jp/all?q=Hepatitis%20B,%20Chronic","dc:title":"Hepatitis B, Chronic"},{"@id":"https://cir.nii.ac.jp/all?q=Treatment%20Outcome","dc:title":"Treatment Outcome"},{"@id":"https://cir.nii.ac.jp/all?q=Humans","dc:title":"Humans"},{"@id":"https://cir.nii.ac.jp/all?q=Drug%20Therapy,%20Combination","dc:title":"Drug Therapy, Combination"},{"@id":"https://cir.nii.ac.jp/all?q=Female","dc:title":"Female"},{"@id":"https://cir.nii.ac.jp/all?q=Hepatitis%20B%20e%20Antigens","dc:title":"Hepatitis B e Antigens"}],"project":[{"@id":"https://cir.nii.ac.jp/crid/1040000782166637440","@type":"Project","projectIdentifier":[{"@type":"KAKEN","@value":"23590985"},{"@type":"JGN","@value":"JP23590985"},{"@type":"URI","@value":"https://kaken.nii.ac.jp/grant/KAKENHI-PROJECT-23590985/"}],"notation":[{"@language":"ja","@value":"肝細胞内微量Ｂ型肝炎ウイルスの病的意義に関する研究"},{"@language":"en","@value":"Pathogenesis of hepatitis B virus in hepatocyte, undetectable in peripheral blood"}]},{"@id":"https://cir.nii.ac.jp/crid/1040000782259187840","@type":"Project","projectIdentifier":[{"@type":"KAKEN","@value":"25461006"},{"@type":"JGN","@value":"JP25461006"},{"@type":"URI","@value":"https://kaken.nii.ac.jp/grant/KAKENHI-PROJECT-25461006/"}],"notation":[{"@language":"ja","@value":"B型肝炎におけるマイクロRNAを用いた肝線維化マーカーの開発"},{"@language":"en","@value":"MicroRNA as a liver fibrosis marker in chronic hepatitis B"}]}],"relatedProduct":[{"@id":"https://cir.nii.ac.jp/crid/1050022476722646656","@type":"Article","resourceType":"学術雑誌論文(journal article)","relationType":["isReferencedBy"],"jpcoar:relatedTitle":[{"@language":"en","@value":"Sequential therapy involving an early switch from entecavir to pegylated interferon-α in Japanese patients with chronic hepatitis B"},{"@language":"ja-Kana","@value":"ニホンジン マンセイ Bガタ カンエン カンジャ ニオケル エンテカビル カラ ペグインターフェロンα エノ ソウキ キリカエ オ トモナウ チクジ リョウホウ"},{"@language":"ja","@value":"日本人慢性B型肝炎患者における、エンテカビルからペグインターフェロンαへの早期切り替えを伴う逐次療法"},{"@value":"Sequential therapy involving an early switch from entecavir to pegylated interferon‐α in Japanese patients with chronic hepatitis B"}]},{"@id":"https://cir.nii.ac.jp/crid/1360011143713081984","@type":"Article","relationType":["references"],"jpcoar:relatedTitle":[{"@value":"Asian-Pacific consensus statement on the management of chronic hepatitis B: a 2008 update"}]},{"@id":"https://cir.nii.ac.jp/crid/1360011143738569216","@type":"Article","relationType":["references"],"jpcoar:relatedTitle":[{"@value":"Sequential treatment with lamivudine and interferon-  monotherapies in hepatitis B e antigen-negative Chinese patients and its suppression of lamivudine-resistant mutations"}]},{"@id":"https://cir.nii.ac.jp/crid/1360011146546429184","@type":"Article","relationType":["references"],"jpcoar:relatedTitle":[{"@value":"Management of HBV infection in Japan"}]},{"@id":"https://cir.nii.ac.jp/crid/1360283693139692416","@type":"Article","resourceType":"学術雑誌論文(journal article)","relationType":["isReferencedBy"],"jpcoar:relatedTitle":[{"@value":"Factors associated with the effect of interferon‐α sequential therapy in order to discontinue nucleoside/nucleotide analog treatment in patients with chronic hepatitis B"}]},{"@id":"https://cir.nii.ac.jp/crid/1360285706236945920","@type":"Article","resourceType":"学術雑誌論文(journal article)","relationType":["isReferencedBy"],"jpcoar:relatedTitle":[{"@value":"Combination therapy with a nucleos(t)ide analogue and interferon for chronic hepatitis B: simultaneous or sequential"}]},{"@id":"https://cir.nii.ac.jp/crid/1360285709456608384","@type":"Article","resourceType":"学術雑誌論文(journal article)","relationType":["isReferencedBy"],"jpcoar:relatedTitle":[{"@value":"Long-Term Outcome of Sequential Therapy with Lamivudine Followed by Interferon-β in Nucleoside-Naive, Hepatitis B e-Antigen-Positive Patients with Chronic Hepatitis B Virus Genotype C Infection"}]},{"@id":"https://cir.nii.ac.jp/crid/1360285714965416192","@type":"Article","resourceType":"学術雑誌論文(journal article)","relationType":["isReferencedBy"],"jpcoar:relatedTitle":[{"@value":"Antiviral therapy for chronic hepatitis B: Combination of nucleoside analogs and interferon"}]},{"@id":"https://cir.nii.ac.jp/crid/1360290617824940288","@type":"Article","resourceType":"学術雑誌論文(journal article)","relationType":["isReferencedBy"],"jpcoar:relatedTitle":[{"@value":"Pilot study of tenofovir disoproxil fumarate and pegylated interferon-alpha 2a add-on therapy in Japanese patients with chronic hepatitis B"}]},{"@id":"https://cir.nii.ac.jp/crid/1360292619315502592","@type":"Article","relationType":["references"],"jpcoar:relatedTitle":[{"@value":"Serological detection of hepatitis B virus genotypes by ELISA with monoclonal antibodies to type-specific epitopes in the preS2-region product"}]},{"@id":"https://cir.nii.ac.jp/crid/1360565168116348928","@type":"Article","resourceType":"学術雑誌論文(journal article)","relationType":["isReferencedBy"],"jpcoar:relatedTitle":[{"@value":"JSH Guidelines for the Management of Hepatitis B Virus Infection"}]},{"@id":"https://cir.nii.ac.jp/crid/1360567181214789888","@type":"Article","resourceType":"学術雑誌論文(journal article)","relationType":["isReferencedBy"],"jpcoar:relatedTitle":[{"@value":"Combinational use of hepatitis B viral antigens predicts responses to nucleos(t)ide analogue/peg-interferon sequential therapy"}]},{"@id":"https://cir.nii.ac.jp/crid/1360567189633761024","@type":"Article","resourceType":"学術雑誌論文(journal article)","relationType":["isReferencedBy"],"jpcoar:relatedTitle":[{"@value":"Reduction of hepatitis B surface antigen in sequential versus add-on pegylated interferon to nucleoside/nucleotide analogue therapy in HBe-antigen-negative chronic hepatitis B patients: A pilot study"}]},{"@id":"https://cir.nii.ac.jp/crid/1360574094762954752","@type":"Article","relationType":["references"],"jpcoar:relatedTitle":[{"@value":"Efficacy of 6-month interferon therapy in chronic hepatitis B virus infection in Japan"}]},{"@id":"https://cir.nii.ac.jp/crid/1360574095163403648","@type":"Article","relationType":["references"],"jpcoar:relatedTitle":[{"@value":"Fully automated quantitation of Hepatitis B virus (HBV) DNA in human plasma by the COBAS® AmpliPrep/COBAS® TaqMan® System☆, ☆☆"}]},{"@id":"https://cir.nii.ac.jp/crid/1360574095571862528","@type":"Article","relationType":["references"],"jpcoar:relatedTitle":[{"@value":"Risk of Hepatocellular Carcinoma Across a Biological Gradient of Serum Hepatitis B Virus DNA Level"}]},{"@id":"https://cir.nii.ac.jp/crid/1360574095600485760","@type":"Article","relationType":["references"],"jpcoar:relatedTitle":[{"@value":"Prediction of Sustained Response to Peginterferon Alfa-2b for Hepatitis B e Antigen–Positive Chronic Hepatitis B Using on-Treatment Hepatitis B Surface Antigen Decline"}]},{"@id":"https://cir.nii.ac.jp/crid/1360574096064720000","@type":"Article","relationType":["references"],"jpcoar:relatedTitle":[{"@value":"Hepatitis B virus infection"}]},{"@id":"https://cir.nii.ac.jp/crid/1360574096488884480","@type":"Article","relationType":["references"],"jpcoar:relatedTitle":[{"@value":"Quantitative detection of hepatitis B surface antigen by chemiluminescent microparticle immunoassay during lamivudine treatment of chronic hepatitis B virus carriers"}]},{"@id":"https://cir.nii.ac.jp/crid/1360848660687481088","@type":"Article","resourceType":"学術雑誌論文(journal article)","relationType":["references"],"jpcoar:relatedTitle":[{"@value":"Combination of hepatitis B viral antigens and DNA for prediction of relapse after discontinuation of nucleos(t)ide analogs in patients with chronic hepatitis B"}]},{"@id":"https://cir.nii.ac.jp/crid/1360855569092374784","@type":"Article","relationType":["references"],"jpcoar:relatedTitle":[{"@value":"Hepatitis B Virus Infection"}]},{"@id":"https://cir.nii.ac.jp/crid/1361137043889852160","@type":"Article","relationType":["references"],"jpcoar:relatedTitle":[{"@value":"Lamivudine/pegylated interferon alfa‐2b sequential combination therapy compared with lamivudine monotherapy in HBeAg‐negative chronic hepatitis B"}]},{"@id":"https://cir.nii.ac.jp/crid/1361137045436302080","@type":"Article","relationType":["references"],"jpcoar:relatedTitle":[{"@value":"Long-term monitoring shows hepatitis B virus resistance to entecavir in nucleoside-naïve patients is rare through 5 years of therapy #"}]},{"@id":"https://cir.nii.ac.jp/crid/1361137045509395840","@type":"Article","relationType":["references"],"jpcoar:relatedTitle":[{"@value":"Sensitive Enzyme Immunoassay for Hepatitis B Virus Core-Related Antigens and Their Correlation to Virus Load"}]},{"@id":"https://cir.nii.ac.jp/crid/1361418520363888640","@type":"Article","relationType":["references"],"jpcoar:relatedTitle":[{"@value":"Geographic distribution of hepatitis B virus (HBV) genotype in patients with chronic HBV infection in Japan"}]},{"@id":"https://cir.nii.ac.jp/crid/1361699993828660224","@type":"Article","relationType":["references"],"jpcoar:relatedTitle":[{"@value":"Hepatitis B Virus Immunopathogenesis"}]},{"@id":"https://cir.nii.ac.jp/crid/1361699993865715200","@type":"Article","relationType":["references"],"jpcoar:relatedTitle":[{"@value":"A Comparison of Entecavir and Lamivudine for HBeAg-Positive Chronic Hepatitis B"}]},{"@id":"https://cir.nii.ac.jp/crid/1361699994191585152","@type":"Article","relationType":["references"],"jpcoar:relatedTitle":[{"@value":"A partially overlapping treatment course with lamivudine and interferon in hepatitis B e antigen‐negative chronic hepatitis B"}]},{"@id":"https://cir.nii.ac.jp/crid/1361699994963641728","@type":"Article","relationType":["references"],"jpcoar:relatedTitle":[{"@value":"A Randomized, Controlled Trial of Interferon Alfa-2b Alone and after Prednisone Withdrawal for the Treatment of Chronic Hepatitis B"}]},{"@id":"https://cir.nii.ac.jp/crid/1361699996121626240","@type":"Article","relationType":["references"],"jpcoar:relatedTitle":[{"@value":"Pegylated interferon alfa-2b alone or in combination with lamivudine for HBeAg-positive chronic hepatitis B: a randomised trial"}]},{"@id":"https://cir.nii.ac.jp/crid/1361699996200230144","@type":"Article","relationType":["references"],"jpcoar:relatedTitle":[{"@value":"Predicting Cirrhosis Risk Based on the Level of Circulating Hepatitis B Viral Load"}]},{"@id":"https://cir.nii.ac.jp/crid/1361981468351019136","@type":"Article","relationType":["references"],"jpcoar:relatedTitle":[{"@value":"Chronic hepatitis B: Update 2009 #"}]},{"@id":"https://cir.nii.ac.jp/crid/1361981469184338432","@type":"Article","relationType":["references"],"jpcoar:relatedTitle":[{"@value":"Guidelines for the treatment of chronic hepatitis and cirrhosis due to hepatitis B virus infection for the fiscal year 2008 in Japan"}]},{"@id":"https://cir.nii.ac.jp/crid/1361981469325770112","@type":"Article","relationType":["references"],"jpcoar:relatedTitle":[{"@value":"Lamivudine and IFN-\n                    <i>β</i>\n                    Sequential Therapy in HBe Antigen-Positive Patients with Chronic Hepatitis B Virus Genotype C Infection"}]},{"@id":"https://cir.nii.ac.jp/crid/1361981469558910080","@type":"Article","relationType":["references"],"jpcoar:relatedTitle":[{"@value":"Lamivudine treatment can restore T cell responsiveness in chronic hepatitis B."}]},{"@id":"https://cir.nii.ac.jp/crid/1361981469656179968","@type":"Article","relationType":["references"],"jpcoar:relatedTitle":[{"@value":"A controlled trial of interferon with or without prednisone priming for chronic hepatitis B"}]},{"@id":"https://cir.nii.ac.jp/crid/1361981470478807936","@type":"Article","relationType":["references"],"jpcoar:relatedTitle":[{"@value":"Peginterferon Alfa-2a, Lamivudine, and the Combination for HBeAg-Positive Chronic Hepatitis B"}]},{"@id":"https://cir.nii.ac.jp/crid/1362262943919457152","@type":"Article","relationType":["references"],"jpcoar:relatedTitle":[{"@value":"Effect of nucleoside analog‐interferon sequential therapy on patients with acute exacerbation of chronic hepatitis B"}]},{"@id":"https://cir.nii.ac.jp/crid/1362262946294234752","@type":"Article","relationType":["references"],"jpcoar:relatedTitle":[{"@value":"Entecavir versus Lamivudine for Patients with HBeAg-Negative Chronic Hepatitis B"}]},{"@id":"https://cir.nii.ac.jp/crid/1362544420268783744","@type":"Article","relationType":["references"],"jpcoar:relatedTitle":[{"@value":"Tenofovir Disoproxil Fumarate versus Adefovir Dipivoxil for Chronic Hepatitis B"}]},{"@id":"https://cir.nii.ac.jp/crid/1362825895291305984","@type":"Article","relationType":["references"],"jpcoar:relatedTitle":[{"@value":"Sequential therapy with adefovir dipivoxil and pegylated Interferon Alfa-2a for HBeAg-negative patients"}]},{"@id":"https://cir.nii.ac.jp/crid/1362825895519109760","@type":"Article","relationType":["references"],"jpcoar:relatedTitle":[{"@value":"Clinical evaluation of a new enzyme immunoassay for hepatitis B virus core‐related antigen; a marker distinct from viral DNA for monitoring lamivudine treatment"}]},{"@id":"https://cir.nii.ac.jp/crid/1363388844075299840","@type":"Article","relationType":["references"],"jpcoar:relatedTitle":[{"@value":"An Algorithm for the Grading of Activity in Chronic Hepatitis C"}]},{"@id":"https://cir.nii.ac.jp/crid/1363388844353237376","@type":"Article","relationType":["references"],"jpcoar:relatedTitle":[{"@value":"Rapid detection of drug-resistant mutations in hepatitis B virus by the PCR-Invader assay"}]},{"@id":"https://cir.nii.ac.jp/crid/1363670318720292480","@type":"Article","relationType":["references"],"jpcoar:relatedTitle":[{"@value":"Sequential treatment with lamivudine and interferon monotherapies in patients with chronic hepatitis B not responding to interferon alone: Results of a pilot study"}]},{"@id":"https://cir.nii.ac.jp/crid/1363951793444013952","@type":"Article","relationType":["references"],"jpcoar:relatedTitle":[{"@value":"EASL Clinical Practice Guidelines: Management of chronic hepatitis B"}]},{"@id":"https://cir.nii.ac.jp/crid/1390282679771619840","@type":"Article","relationType":["isReferencedBy"],"jpcoar:relatedTitle":[{"@language":"en","@value":"Two cases of acute hepatitis due to hepatitis E virus that are indigenous to Kitakyushu: a case report"},{"@language":"ja","@value":"北九州に土着したE型肝炎ウイルス株による急性肝炎の2例"},{"@value":"B型肝炎治療ガイドライン(第1.1版)"},{"@language":"ja-Kana","@value":"Bガタ カンエン チリョウ ガイドライン(ダイ1.1ハン)"},{"@language":"ja-Kana","@value":"キタキュウシュウ ニ ドチャク シタ Eガタ カンエンウイルスカブ ニ ヨル キュウセイ カンエン ノ 2レイ"},{"@value":"Guidelines for the management of hepatitis B virus infection"}]}],"dataSourceIdentifier":[{"@type":"CROSSREF","@value":"10.1007/s00535-012-0645-5"},{"@type":"KAKEN","@value":"PRODUCT-14149241"},{"@type":"KAKEN","@value":"PRODUCT-15077959"},{"@type":"KAKEN","@value":"PRODUCT-14149221"},{"@type":"OPENAIRE","@value":"doi_dedup___::b89a8fcccb669abc3fee775eddbdf4e6"},{"@type":"CROSSREF","@value":"10.3851/imp3240_references_DOI_BfQqSLjJsjjlJ0k0CvUKjovTjpy"},{"@type":"CROSSREF","@value":"10.1111/hepr.12488_references_DOI_BfQqSLjJsjjlJ0k0CvUKjovTjpy"},{"@type":"CROSSREF","@value":"10.1007/s00535-012-0742-5_references_DOI_BfQqSLjJsjjlJ0k0CvUKjovTjpy"},{"@type":"CROSSREF","@value":"10.1089/jir.2014.0234_references_DOI_BfQqSLjJsjjlJ0k0CvUKjovTjpy"},{"@type":"CROSSREF","@value":"10.4254/wjh.v7.i23.2427_references_DOI_BfQqSLjJsjjlJ0k0CvUKjovTjpy"},{"@type":"CROSSREF","@value":"10.1007/s00535-020-01707-6_references_DOI_BfQqSLjJsjjlJ0k0CvUKjovTjpy"},{"@type":"CROSSREF","@value":"10.1111/hepr.13050_references_DOI_BfQqSLjJsjjlJ0k0CvUKjovTjpy"},{"@type":"CROSSREF","@value":"10.1111/hepr.12269_references_DOI_BfQqSLjJsjjlJ0k0CvUKjovTjpy"},{"@type":"CROSSREF","@value":"10.1007/s00535-017-1360-z_references_DOI_BfQqSLjJsjjlJ0k0CvUKjovTjpy"},{"@type":"CROSSREF","@value":"10.2957/kanzo.54.402_references_DOI_BfQqSLjJsjjlJ0k0CvUKjovTjpy"}]}